Effective induction of high-titer antibodies by viral vector vaccines

被引：125

作者：

Draper, Simon J. ^{[1
]}

Moore, Anne C. ^{[1
]}

Goodman, Anna L. ^{[1
]}

Long, Carole A. ^{[2
]}

Holder, Anthony A. ^{[3
]}

Gilbert, Sarah C. ^{[1
]}

Hill, Fergal ^{[4
]}

Hill, Adrian V. S. ^{[1
]}

机构：

[1] Univ Oxford, Jenner Inst, Oxford OX3 7DQ, England

[2] NIAID, Lab Malaria & Vector Res, US NIH, Rockville, MD 20852 USA

[3] Natl Inst Med Res, Div Parasitol, London NW7 1AA, England

[4] Imaxio, F-69007 Lyon, France

来源：

NATURE MEDICINE | 2008年 / 14卷 / 08期

基金：

英国医学研究理事会; 英国惠康基金;

关键词：

D O I：

10.1038/nm.1850

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Protein-in-adjuvant vaccines have shown limited success against difficult diseases such as blood-stage malaria. Here we show that a recombinant adenovirus-poxvirus prime-boost immunization regime (known to induce strong T cell immunogenicity) can also induce very strong antigen-specific antibody responses, and we identify a simple complement-based adjuvant to further enhance immunogenicity. Antibodies induced against a blood-stage malaria antigen by this viral vector platform are highly effective against Plasmodium yoelii parasites in mice and against Plasmodium falciparum in vitro.

引用

收藏

页码：819 / 821

页数：3

相关论文

共 16 条

[1] Protective immune responses to the 42-kilodalton (kDa) region of Plasmodium yoelii merozoite surface protein 1 are induced by the C-terminal 19-kDa region but not by the adjacent 33-kDa region [J].

Ahlborg, N ;

Ling, IT ;

Howard, W ;

Holder, AA ;

Riley, EM .

INFECTION AND IMMUNITY, 2002, 70 (02) :820-825

[2] Complement inhibitor C4b-binding protein -: friend or foe in the innate immune system? [J].

Blom, AM ;

Villoutreix, BO ;

Dahlbäck, B .

MOLECULAR IMMUNOLOGY, 2004, 40 (18) :1333-1346

[3] C4b-binding protein (C4BP) activates B cells through the CD40 receptor [J].

Brodeur, SR ;

Angelini, F ;

Bacharier, LB ;

Blom, AM ;

Mizoguchi, E ;

Fujiwara, H ;

Plebani, A ;

Notarangelo, LD ;

Dahlback, B ;

Tsitsikov, E ;

Geha, RS .

IMMUNITY, 2003, 18 (06) :837-848

[4] Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen [J].

Bruña-Romera, O ;

González-Aseguinolaza, G ;

Hafalla, JCR ;

Tsuji, M ;

Nussenzweig, RS .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (20) :11491-11496

[5] Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector [J].

Catanzaro, Andrew T. ;

Koup, Richard A. ;

Roederer, Mario ;

Bailer, Robert T. ;

Enama, Mary E. ;

Moodie, Zoe ;

Gu, Lin ;

Martin, Julie E. ;

Novik, Laura ;

Chakrabarti, Bimal K. ;

Butman, Bryan T. ;

Gall, Jason G. D. ;

King, C. Richter ;

Andrews, Charla A. ;

Sheets, Rebecca ;

Gomez, Phillip L. ;

Mascola, John R. ;

Nabel, Gary J. ;

Graham, Barney S. .

JOURNAL OF INFECTIOUS DISEASES, 2006, 194 (12) :1638-1649

[6] Asexual blood-stage malaria vaccine development: facing the challenges [J].

Genton, Blaise ;

Reed, Zarifah H. .

CURRENT OPINION IN INFECTIOUS DISEASES, 2007, 20 (05) :467-475

[7] Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes [J].

Gilbert, SC ;

Schneider, J ;

Hannan, CM ;

Hu, JT ;

Plebanski, M ;

Sinden, R ;

Hill, AVS .

VACCINE, 2002, 20 (7-8) :1039-1045

[8] Disulfide bonds in merozoite surface protein 1 of the malaria parasite impede efficient antigen processing and affect the in vivo antibody response [J].

Hensmann, M ;

Li, C ;

Moss, C ;

Lindo, V ;

Greer, F ;

Watts, C ;

Ogun, SA ;

Holder, AA ;

Langhorne, J .

EUROPEAN JOURNAL OF IMMUNOLOGY, 2004, 34 (03) :639-648

[9] Pre-erythrocytic malaria vaccines: towards greater efficacy [J].

Hill, AVS .

NATURE REVIEWS IMMUNOLOGY, 2006, 6 (01) :21-32

[10]

Hirunpetcharat C, 1997, J IMMUNOL, V159, P3400